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Abstract
Background: Amino acids in the β subunit contribute to the action of general anaesthetics on
GABAA receptors. We have now characterized the phenotypic effect of two β subunit mutations
in the most abundant GABAA receptor subtype, α1β2γ2.
Results:  The  β2(N265M) mutation in M2 decreased the modulatory actions of propofol,
etomidate and enflurane, but not of alphaxalone, while the direct actions of propofol, etomidate
and alphaxalone were impaired. The β2(M286W) mutation in M3 decreased the modulatory
actions of propofol, etomidate and enflurane, but not of alphaxalone, whereas the direct action of
propofol and etomidate, but not of alphaxalone, was impaired.
Conclusions:  We found that the actions of general anaesthetics at α1β2(N265M)γ2 and
α1β2(M286W)γ2 GABAA receptors are similar to those previously observed at α2β3(N265M)γ2
and α2β3(M286W)γ2 GABAA recpetors, respectively, with the notable exceptions that the direct
action of propofol was decreased in α1β2(M286W)γ2 receptors but indistinguishable form wild
type in α2β3(M286W)γ2 receptors and that the direct action of alphaxalone was decreased in
α1β2(N265M)γ2 but not α2β3(N265M)γ2 receptors and indistinguishable form wild type in
α1β2(M286W)γ2 receptors but increased in α2β3(M286W)γ2 receptors. Thus, selected
phenotypic consequences of these two mutations are GABAA receptor subtype-specific.
Background
General anaesthetics are among the medically most
widely used and important drugs. However, their mecha-
nism of action is still poorly understood. They modulate
the activity of ligand-gated ion channels (for review see
[1,2]). In particular, at surgical concentrations, most gen-
eral anaesthetics potentiate GABAA  receptor-mediated
responses. Amino acids have been identified in the second
and third transmembrane regions (TM2 and TM3) of α
and β subunits which appear to be necessary for the action
of general anaesthetics on the GABAA  receptor. These
include in TM2 an asparagine at position 265 of the β3
subunit and in TM3 a methionine at position 286 in β1 or
β3 [3–6]. Most electrophysiological studies have been per-
formed using αβ subunit combinations, whereas most
GABAA receptors in the central nervous system apparently
consist of α, β and γ subunits. The presence of a γ subunit
may alter the effects of a mutation at these residues [7].
Moreover, various combinations of α and β subunits
might also confer distinct properties on the respective
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receptors. In particular, it is not known which functional
consequences a mutation in the TM2 or TM3 region of the
β subunit would have on the by far most abundant GABAA
receptor subtype in the CNS, α1β2γ2, which represents ca.
50% of all GABAA receptors [8]. The α1β2γ2 GABAA recep-
tor is an interesting candidate for mediating anaesthetic
responses in vivo. We therefore investigated the pharmaco-
logical properties of recombinant α1β2γ2 receptors carry-
ing the β2(N265M) and β2(M286W) mutations to assess
their suitability as potential knock-in point mutations in
mice.
Results
GABA-sensitivity of wild-type and point-mutated 
recombinant α1β2γ2 GABAA receptors
To determine the relevance of the amino acids N265 and
M286 in the GABAA receptor β2 subunit for the action of
general anaesthetics on the α1β2γ2 GABAA receptor, we
introduced the point mutations β2(N265M) and
β2(M286W) by site directed mutagenesis. Wild-type and
mutant β2 subunits were coexpressed with α1 and γ2 sub-
units in HEK 293 cells.
The GABA EC50 value for the α1β2γ2 receptor was 5.9 ±
0.5 µM (n = 8), in line with previously published reports
(4.5–20 µM) [9–12] (Fig. 1). The presence of the γ2 subu-
nit in the receptor complex was confirmed by the observa-
tion that 1 µM diazepam potentiate the current evoked by
32 µM GABA by 277 ± 48.2 % (not shown). The GABA
dose-response curve for the α1β2(N265M)γ2 receptor was
shifted to the right with an EC50 of 20 ± 2.2 µM (n = 8)
which was significantly higher than the EC50  of the
α1β2γ2 receptor (5.9 ± 0.5 µM (n = 8); p < 0.05) (Fig. 1).
In contrast, the GABA dose-response curve for the
α1β2(M286W)γ2 receptor was shifted to the left with an
EC50 of 1.9 ± 0.15 µM (n = 8) significantly smaller com-
pared to wild type (p < 0.05) (Fig. 1). The Hill coeffient
was not significantly altered by the two mutations
(α1β2γ2: Hill = 1.4 ± 0.15; α1β2(N265M)γ2: Hill = 1.4 ±
0.2; α1β2(M286W)γ2: Hill = 1.5 ± 0.2). The Imax values for
all receptor combinations were not significantly different
(α1β2γ2: Imax = 1269 ± 524 pA; α1β2(N265M)γ2: Imax =
1944 ± 562 pA (p > 0.05); α1β2(M286W)γ2: Imax = 1947
± 646 pA (p > 0.05)). Thus, whereas the N265M mutation
decreased the sensitivity to GABA, the M286W mutation
led to an increase in the sensitivity to GABA.
Modulation of GABA-induced currents by general 
anaesthetics
To test the modulatory activity of anaesthetics, GABA con-
centrations corresponding to the EC15 were used (α1β2γ2:
3 µM; α1β2(N265M)γ2: 8 µM; α1β2(M286W)γ2: 1 µM).
Propofol
Propofol is a widely used intravenous general anaesthetic
agent. In HEK 293 cells expressing the α1β2γ2 receptor,
10 µM propofol potentiated the GABA-induced chloride
current by 100.7 ± 17% (n = 16). In cells expressing the
α1β2(N265M)γ2 receptor, this potentiation amounted to
43.5 ± 10.1% (n = 10) and thus was significantly smaller
(p < 0.05). Similarly, in cells expressing α1β2(M286W)γ2
receptor the potentiation was 48.4 ± 13.2% (n = 16), and
thus also significantly smaller than in wild type (p < 0.05).
Thus, the β2(N265M) mutation and the β2(M286W)
mutation significantly reduced the potentiation of GABA-
induced chloride currents by propofol (Fig. 2).
Etomidate
Etomidate is also a clinically used intravenous anaes-
thetic. In cells expressing α1β2γ2 receptors, 10 µM etomi-
date potentiated the GABA-induced chloride current by
372 ± 103.4% (n = 10). The potentiation at the
α1β2(N265M)γ2 receptor was significantly smaller (83.7
± 23.5%; n = 13; p < 0.05), as was the potentiation at the
α1β2(M286W)γ2 receptor (87.4 ± 34.1%; n = 11; p <
0.05). Thus, both the β2(N265M) mutation and the
β2(M286W) mutation significantly reduce the potentia-
tion of GABA-induced chloride currents by etomidate
(Fig. 2).
Alphaxalone
5 µM of the neuroactive steroid anaesthetic alphaxalone
potentiated the GABA-induced current in cells expressing
the α1β2γ2 receptor by 327 ± 59.4% (n = 17), in cells
expression the α1β2(N265M)γ2 receptor 346.5 ± 97.4%
(n = 11) and in cells expressing the α1β2(M286W)γ2
GABA dose-response curves for wild-type and point- mutated α1β2γ2 GABAA receptors transiently expressed in  HEK 293 cells Figure 1
GABA dose-response curves for wild-type and point-
mutated α1β2γ2 GABAA receptors transiently expressed in 
HEK 293 cells. The data points and error bars represent the 
means and standard errors for the different GABA concen-
trations (n = 8).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/13
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Modulatory action of intravenous general anesthetic at α1β2γ2 GABAA receptors Figure 2
Modulatory action of intravenous general anesthetic at α1β2γ2 GABAA receptors. (a) Single traces of the effects of the intrave-
nous anaesthetics propofol (Prop), etomidate (Etom) and alphaxalone (Alphax) on GABA-evoked chloride currents. (b) The 
potentiation of the GABA-evoked chloride currents is expressed relative to the control currents at the given GABA concen-
tration (means ± standard error, n = 10–17; *p < 0.05; Student's t-test).BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/13
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receptor by 201.6 ± 45.6% (n = 14). The values obtained
for the mutant receptors were not significantly different
from wild type. Thus, both mutations have no effect on
the potentiation of GABA-induced chloride currents by
alpaxalone (Fig. 2).
Enflurane
Enflurane is a clinically used volatile general anaesthetic.
1 mM enflurane potentiated GABA-induced currents by
119.4 ± 23% (n = 8) in cells expressing the α1β2γ2 recep-
tor, 31.7 ± 10% (n = 13) in cells expressing the
α1β2(N265M)γ2 receptor and 4.8 ± 2.1% (n = 11) in cells
expressing the α1β2(M286W)γ2 receptor (Fig. 3). The val-
ues for both mutant receptors are significantly different
from wild type (p < 0.01). Thus, both mutations signifi-
cantly reduce the potentiation of GABA-induced chloride
currents by enflurane.
Direct activation of GABAA receptors by general 
anaesthetics
At concentrations usually higher than those required for
potentiation of GABA-induced chloride currents,
propofol, etomidate and alphaxalone display a direct ago-
nistic action on GABAA receptors. The direct actions of
these compounds were compared to the maximal GABA
current at the respective receptor, which was determined
separately.
Propofol
50 µM propofol induced a chloride current amounting to
20 ± 7 % (n = 12) of the maximal GABA-induced current,
which was determined separately, in cells expressing the
α1β2γ2 receptor (Fig. 4). In contrast, in cells expressing
the α1β2(N265M)γ2 or α1β2(M286W)γ2 receptors, 50
µM propofol induced chloride currents amounting to
0.7% ± 0.3% (n = 17) and 2.0 ± 0.8% (n = 10), respec-
tively, of the maximal GABA-induced current, thus being
significantly smaller (p < 0.05) compared to wild type
(Fig. 4). Thus, both mutations almost abolish the direct
action of propofol on the α1β2γ2 receptor.
Etomidate
10 µM Etomidate induced a chloride current amounting
to 33 ± 11% (n = 13) of the maximal GABA-induced cur-
rent in cells expressing the α1β2γ2 receptor (Fig. 4). In
cells expressing α1β2(N265M)γ2 or α1β2(M286W)γ2
receptors, this direct effect was significantly reduced to 0.4
± 0.2% (n = 19; p < 0.05) and 2.1 ± 0.5% (n = 10); p <
0.05), respectively (Fig. 4). Thus, the two point mutations
abolish the direct action of etomidate on the α1β2γ2
receptor.
Alphaxalone
10 µM Alphaxalone induced a chloride current amount-
ing to 49.8% ± 18% (n = 12) of the maximal GABA-
induced chloride current in cells expressing the α1β2γ2
receptor (Fig. 4). Whereas the alphaxalone-induced cur-
rent is significantly reduced in cells expressing the
α1β2(N265M)γ2 receptor (5.6 ± 1.2%; n = 19, p < 0.05),
it was non-significantly decreased in cells expressing the
α1β2(M286W)γ2 receptor (31.1 ± 9.1%; n = 9) (Fig. 4).
Thus, while the β2(N265M) mutation significantly
reduces the extent of direct activation by alphaxalone, the
β2(M286W) mutation had no effect.
Discussion
In the present study we assessed the phenotypic conse-
quences of two point mutations in the second (TM2) and
third (TM3) transmembrane domains of the GABAA recep-
tor  β2 subunit, β2(N265M) and β2(M286W), respec-
tively, with respect to GABA sensitivity and the action of
general anaesthetic agents on the most abundant GABAA
receptor subtype in the central nervous system, α1β2γ2.
This is particularly important for potential future analysis
of these mutations in knock-in point-mutated mice.
At amino acid position 265 of the β2 subunit, an asparag-
ine has been replaced by a methionine, which is the cor-
responding residue in the etomidate-insensitive
Drosophila  rdl  receptor. The β3(N265M) mutation
indeed largely abolished the direct and modulatory
actions of etomidate and propofol on α6β3γ2 receptors
[3,13]. In α2β1(S265I) receptors, the potentiation of the
GABA current by enflurane was inhibited by less than
50%, however, the potentiation by isoflurane was com-
pletely abolished, while the potentiating action of
propofol, etomidate, methohexital and alphaxalone was
not changed [4,6]. In the same study, the direct action of
propofol and etomidate, but not methohexital was shown
to be impaired by this mutation [6]. Recently, we showed
that the β3(N265M) mutation, when studied in the
α2β3(N265M)γ2 receptor, almost abolished the modula-
tory actions of propofol and etomidate, but not
alphaxalone, and reduced the modulatory action of enflu-
rane by ca. 80% [14]. Likewise, the direct actions of pro-
pofol and etomidate, but not alphaxalone were almost
abolished [14].
In the present study, we find that the β2(N265M) muta-
tion decreases the sensitivity of the α1β2γ2 receptor for
GABA, with an increase of the EC50 value from 5.9 ± 0.5
µM to 20 ± 2.2 µM. Harrison and colleagues [15] also
reported a shift of the GABA dose-response curve to the
right by this mutation. We show that this mutation signif-
icantly reduces the modulatory action of propofol, etomi-
date and enflurane, but not alphaxalone, similar to what
we previously reported for the α2β3γ2 receptor [14].
Nishikawa et al. [17] recently observed that the modula-
tory action of the volatile anesthetics isoflurane, sevoflu-
rane and desflurane at α1β2(N265M)γ2 receptors is alsoBMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/13
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reduced. In α1β2(N265M)γ2 receptors, the direct action
of etomidate and propofol was completely abolished,
which is in line with the results obtained on the
α2β3(N265M)γ2 receptor, while the direct action of
alphaxalone was significantly reduced, in contrast to our
results obtained on the α2β3(N265M)γ2 receptor [14].
Thus, with the notable exception of the direct action of
alphaxalone, similar results were obtained concerning the
effect on the N265M mutation in the β2 and β3 subunits.
At amino acid position 286 of the β2 subunit, a methio-
nine was replaced by a tryptophane. Tryptophan is the
homologous residue in the GABAA receptor ρ1 subunit,
which is insensitive for general anaesthetics, e.g., enflu-
rane [4]. When the β1(M286W) mutation was studied in
α1β1 receptors, the modulatory action of enflurane was
abolished [4]. When this mutation was introduced into
α2β1 receptors, the modulatory action of isoflurane and
propofol were abolished and the modulatory action of
methohexital reduced, but the modulatory actions of eto-
midate and alphaxalone were unaffected by the mutation
[6]. In contrast, the direct action of etomidate was
decreased, but the direct action of propofol and metho-
hexital were not changed [6]. The same group also found
Modulatory action of the volatile general anaesthetic enflurane at α1β2γ2 GABAA receptors Figure 3
Modulatory action of the volatile general anaesthetic enflurane at α1β2γ2 GABAA receptors. (a) Histogram of the modulation 
of GABA-induced chloride currents by enflurane (means ± standard error, n = 8–13; **p < 0.01; Student's t-test). (b) Single 
traces showing the effects of the volatile anaesthetic enflurane (enflur) on GABA-evoked chloride currents.
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Direct activation of α1β2γ2 GABAA receptors by intravenous general anesthetics Figure 4
Direct activation of α1β2γ2 GABAA receptors by intravenous general anesthetics. (a) Bar histogram of the direct activation of 
GABAA receptor-mediated chloride currents by propofol, etomidate and alphaxalone. Data points represent means ± standard 
error, n = 9–19; *p < 0.05; Student's t-test). (b) Selected traces showing representative whole-cell chloride currents activated 
by propofol, etomidate and alphaxalone.BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/13
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that the GABA sensitivity was unchanged compared to
wild type in the α2β1(M286W) receptor as well as in the
α1β2(M286W)γ2 receptor [6,16]. In the present study,
however, we find that the EC50 of the α1β2(M286W)γ2
receptor is reduced approximately three-fold. Our find-
ings are in line with our observation that the correspond-
ing  β3(M286W) mutation also leads to a similar
reduction of the EC50 in α2β3(M286W)γ2 receptors. The
source of the discrepancies between the results reported
by the two groups are not clear.
For etomidate, Harrison and colleagues reported no sig-
nificant change of the modulatory action on
α2β1(M286W) receptors compared to wild type [6], but a
significant reduction of the modulatory action on the
α1β2(M286W)γ2 receptor compared to wild type (from
237 ± 45% (n = 6) in wild type to 162 ± 11% (n = 5)) [16].
With the same concentration of etomidate (10 µM), we
observed a decrease of the modulatory action from 372 ±
103.4% (n = 10) in wild type to 87.4 ± 34.1% (n = 11; p
< 0.05). In our study, the β2(M286W) mutation had no
significant effect on the modulatory action of
alphaxalone. This is in line with the observation that the
modulatory effect of alphaxalone is indistinguishable
from wild type in α2β1(M286W) and α1β2(M286W)γ2
receptors [6,16] as well as α2β3(M286W)γ2 receptors
[14]. Our finding that the enflurane action is almost com-
pletely abolished in the α1β2(M286W)γ2 receptor also
corresponds with our previous findings on the
α2β3(M286W)γ2 receptor [14]. Whereas the direct action
of propofol on the α2β1(M286W) receptor has been
reported to be indistinguishable from wild type, the direct
action of etomidate was reported to be significantly
reduced in the α2β1(M286W) receptor [6]. In our study,
however, using the same concentration of propofol (50
µM), we found a significant decrease of the direct activa-
tion of the α1β2(M286W)γ2 receptor compared to wild
type. The direct action of etomidate was also significantly
reduced. A reduction of the direct action of propofol on
the α1β2(M286W)γ2 receptor was also reported by [16].
In contrast, we previously reported that the direct action
of propofol is indistinguishable from wild type in the
α2β3(M286W)γ2 receptor [14]. These results are consist-
ent with the notion that the M286W mutation has differ-
ent phenotypic consequences in GABAA receptors with
different αβγ subunit combinations.
A further subtype-specific difference in the direct action of
anaesthetics was observed for the neuroactive steroid
alphaxalone. Whereas the direct effect of alphaxalone on
the  α2β3(M286W)γ2 receptor was significantly higher
compared to wild type, the direct effect of alphaxalone
was indistinguishable from wild type in the
α1β2(M286W)γ2 receptor.
In conclusion, this study demonstrates the consequences
of the β2(N265M) and β2(M286W) mutations on anaes-
thetic actions on the most abundant GABAA receptor sub-
type in the central nervous system, α1β2γ2, indicating
that these mutations are suitable to study the relevance of
this GABAA receptor for general anaesthesia in mice. At the
same time, they demonstrate that the phenotypic conse-
quences of mutations at homologous positions of β sub-
units can vary between receptor subtypes and that
extrapolations should only been done with caution.
Methods
Experimental procedures were similar to those described
previously [14]. Rat α1, β2, and γ2short subunit cDNAs in
the expression vector pBC12/CMV [9] were used in this
study. In the β2 subunit, the asparagine residue at posi-
tion 265 was changed to a methionine residue
[β2(N265M)] and, independently, the methionine resi-
due at position 286 was changed to a tryptophane residue
[β2(M286W)] using the QuikChange® site-directed muta-
genesis kit (Stratagene, La Jolla, California, USA) with
complementary oligonucleotides spanning the muta-
tions. For the [β2(N265M)] mutation, oligonucleotides
SL-3: 
5'-GACGATGACCACAATCATGACCCATCTCCGGGA-
GACTC-3' and SL-4: 
5'-GAGTCTCCCGGAGATGGGTCATGATTGTGGT-
CATCGTC-3' were used (mutated codon underlined). For
the [β2(M286W)] mutation, oligos SL-5: 
5'-GCCATTGACATGTACCTA TGGGGGTGCTTTGTCTTT-
GTC-3' and SL-6: 
5'-ACAAAGACAAAGCACCCCCATAGGTACATGTCAAT-
GGC-3' were used (mutated codon underlined). The
numbering of amino acids is based on the mature protein
after cleavage of the signal peptide.
Human embryonic kidney cells 293 (HEK 293) were
grown in Dulbecco's modified Eagle medium (DMEM,
Gibco, Invitrogen, Basel, Switzerland) supplemented with
5% heat inactivated fetal calf serum (FCS, Gibco, Invitro-
gen, Basel, Switzerland), 100 U/ml penicillin and 100 mg/
ml streptomycin (both from Gibco, Invitrogen, Basel,
Switzerland). Cells were transiently transfected using the
calcium phosphate precipitation technique.
The patch-clamp technique in the whole-cell configura-
tion was used to record GABA-induced Cl- currents. The
membrane potential was held at -60 mV. The current sig-
nals were amplified with an Axopatch-1D amplifier (Axon
Instruments, Inc., Foster City, CA, USA), filtered by a 1
KHz four-pole Bessel low-pass filter. The analysis of data
was performed using the pClamp data acquisition pro-
gram set (pClamp 8.0, Axon Instruments) and FigP (Bio-
soft, Cambridge, UK). The GABA dose-response curves
were obtained by applying 5-sec pulses of GABA every 1.5BMC Pharmacology 2003, 3 http://www.biomedcentral.com/1471-2210/3/13
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min to the patch-clamped HEK 293 cells. The maximum
current amplitudes from individual cells were first fitted
separately using the equation I/Imax  = 1/ (1+ (EC50/
[GABA])Hill), where I is GABA-evoked current, Imax is the
maximum of the fit, EC50 is the GABA concentration evok-
ing the half-maximal response, and Hill is the Hill coeffi-
cient. The individual dose-response curves were then
normalized to Imax, and the data replotted using the mean
values for each concentration.
Drug application
GABA was applied in the presence or absence of drugs to
the patch-clamped cell for 5 sec every 1.5 min using a
multibarrelled microapplicator pipette constructed from
seven concentrically arranged glass tubes ending in a com-
mon tip. Air-tight syringes, containing the solutions, were
connected to the microapplicator via Teflon tubes, in
order to avoid loss of the anaesthetics due to evaporation
or sticking to the tubes. Six of the tubes were used for drug
delivery, and the seventh tube at the center provided slow
aspiration to prevent accumulation of drugs in the com-
mon tip and leakage from the inactive barrels. To allow a
rapid shut-off of the drug application, a sucking pipette
was placed in front of the tip of the drug-applicator, in
order that the tested cell was positioned between the
applicator and the suction. In this way, the solution com-
ing from the application bathed the cell and was directly
and rapidly sucked out by the suction.
Solutions and drugs
The recording pipettes were filled with an intracellular
saline solution containing 120 mM CsCl, 20 mM TEACl,
1 mM CaCl2, 2 mM MgCl2, 11 mM EGTA, 10 mM HEPES,
adjusted to pH 7.2 with CsOH. The cells, placed in a petri-
dish fitting into the recording chamber, were continu-
ously superfused with a bath solution using a second
applicator. The bath solution contained 157 mM NaCl,
5.4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM
HEPES, adjusted to pH 7.4 with NaOH. The experiments
were performed at room temperature. GABA was from
Sigma (St. Louis, Mo, USA), etomidate from Janssen Phar-
maceutica (Beerse, Belgium). Propofol from Aldrich
(Buchs, Switzerland), alphaxalone from Sigma (Buchs,
Switzerland) and enflurane from Abbott Laboratories
(Cham/ Zug, Switzerland). GABA was dissolved in water
and used at concentrations of 3 µM for α1β2γ2 receptors, 8
µM α1β2(N265M)γ2 receptors and of 1 µM for α1β2(M286W)γ2
receptors, which correspond to EC15  for all receptors.
Stock solutions of the test compounds were prepared in
100 % DMSO and diluted 1000-fold before use. During
the experiments, the final concentrations of DMSO in the
bath solutions were not higher than 0.1 %, which had no
effect on GABA responses. The volatile enflurane was dis-
solved in the external solution. Fresh solutions were pre-
pared every hour. We expect only a small loss of enflurane
of ca. 10% to 15%, which would affect recordings from
wild type and mutant receptors in the same way.
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